DuPont (NYSE: DD) today announced it has signed an agreement to acquire Donatelle Plastics Incorporated, a leading medical device contract manufacturer specializing in the design, development and manufacture of medical components and devices. The transaction is expected to close in the third quarter 2024, subject to satisfaction of customary closing conditions and receipt of regulatory approvals. "Our healthcare strategy is focused on offering a comprehensive suite of solutions for customers in high-growth therapeutic areas," said Jon Kemp, President, DuPont Electronics & Industrial (E&I).
"Donatelle Plastics Incorporated will be the second acquisition, following Spectrum last year, that will deepen our expertise in the medical device market segments and enhance our position as a partner of choice for our customers.” DuPont’s healthcare exposure within the Industrial Solutions line of business of the E&I segment includes Spectrum, a leader in medical device components, and LiveoTM, a leader in silicone solutions for healthcare applications. The acquisition of Donatelle Plastics Incorporated will bring complementary advanced technologies and capabilities including medical device injection molding, liquid silicone rubber processing, precision machining, device assembly, and tool building.
Donatelle Plastics Incorporated has a strong financial growth profile aligned to attractive therapeutic areas including electrophysiology, drug delivery, diagnostics, cardiac rhythm manage.
